The Interaction between GSTT1, GSTM1, and GSTP1 Ile105Val Gene Polymorphisms and Environmental Risk Factors in Premalignant Gastric Lesions Risk
Table 3
The gene-environment interaction in endoscopic and premalignant gastric lesions.
Factors
Genotype
Without endoscopic lesions versus mild or severe endoscopic lesions
Adjusted OR‡ [95% CI]
Without premalignant lesions versus with premalignant lesions
Adjusted OR‡ (95% CI)
H. pylori
GSTP1 Ile105Val
Negative
Ile/Ile
56/40
1 (reference)
44/52
1 (reference)
Ile/Val + Val/Val
63/26
0.55 [0.29, 1.04]
55/34
0.47 [0.26, 0.87]
Positive
Ile/Ile
29/21
1.00 [0.48, 2.07]
24/26
0.86 [0.42, 1.77]
Ile/Val + Val/Val
21/14
0.70 [0.32, 1.54]
18/17
0.56 [0.26, 1.22]
value for interaction = 0.676
value for interaction = 0.568
H. pylori
GSTT1
Negative
T1
96/49
1 (reference)
77/68
1 (reference)
Null
23/17
1.40 [0.65, 2.98]
22/18
1.00 [0.47, 2.12]
Positive
T1
38/31
1.39 [0.75, 2.57]
33/36
1.06 [0.58, 1.57]
Null
12/4
0.53 [0.16, 1.73]
9/7
0.71 [0.25, 2.01]
value for interaction = 0.087
value for interaction = 0.576
H. pylori
GSTM1
Negative
M1
69/26
1 (reference)
56.39
1 (reference)
Null
50/40
2.23 [1.20, 4.37]
43/47
1.66 [0.90, 3.07]
Positive
M1
21/18
2.07 [0.92, 4.69]
21/18
1.04 [0.47, 2.30]
Null
29/17
1.46 [0.69, 3.09]
21/25
1.57 [0.77, 3.19]
value for interaction = 0.038
value for interaction = 0.858
Alcohol
GSTP1 Ile105Val
No
Ile/Ile
67/47
1 (reference)
52/62
1 (reference)
Ile/Val + Val/Val
62/27
0.60 [0.32, 1.11]
55/34
0.49 [0.27, 0.87]
Yes
Ile/Ile
18/14
0.78 [0.32, 1.90]
16/16
0.64 [0.26, 1.55]
Ile/Val + Val/Val
22/13
0.44 [0.20, 0.96]
18/17
0.42 [0.20, 0.90]
value for interaction = 0.909
value for interaction = 0.628
Alcohol
GSTT1
No
T1
104/63
1 (reference)
22/14
1 (reference)
Null
25/11
0.72 [0.31, 1.60]
85/82
0.72 [0.33, 1.54]
Yes
T1
30/17
0.59 [0.25, 1.35]
9/11
0.59 [0.25, 1.34]
Null
10/10
1.01 [0.32, 2.07]
25/22
0.85 [0.34, 2.16]
value for interaction = 0.214
value for interaction = 0.328
Alcohol
GSTM1
No
M1
74/32
1 (reference)
64/42
1 (reference)
Null
55/42
1.83 [1.00, 3.37]
43/54
2.13 [1.19, 3.83]
Yes
M1
16/12
1.08 [0.41, 2.76]
13/15
1.40 [0.54, 3.67]
Null
24/15
0.99 [0.46, 2.13]
21/18
0.81 [0.28, 1.53]
value for interaction = 0.256
value for interaction = 0.041
Smoking
GSTP1 Ile105Val
No
Ile/Ile
78/58
1 (reference)
66/70
1 (reference)
Ile/Val + Val/Val
79/32
0.51 [0.29, 0.89]
70/41
0.51 [0.30, 0.87]
Yes
Ile/Ile
7/3
0.76 [0.15, 3.17]
2/8
5.14 [1.15, 36.52]
Ile/Val + Val/Val
5/8
1.97 [0.61, 6.33]
3/10
3.46 [0.91, 13.13]
value for interaction = 0.090
value for interaction = 0.790
Smoking
GSTT1
No
T1
126/72
1 (reference)
107/91
1 (reference)
Null
31/18
1.06 [0.53, 2.10]
29/20
0.94 [0.48, 1.82]
Yes
T1
8/8
2.23 [0.70, 7.14]
3/13
7.36 [2.04, 35.67]
Null
4/3
1.21 [0.26, 5.56]
2/5
3.87 [0.73, 20.43]
value for interaction = 0.503
value for interaction = 0.609
Smoking
GSTM1
No
M1
87/40
1 (reference)
76/51
1 (reference)
Null
70/50
1.68 [0.97, 2.93]
60/60
1.67 [0.99, 2.85]
Yes
M1
3/4
3.69 [0.71, 21.11]
1/6
11.08 [1.68, 220.49]
Null
9/7
2.17 [0.75, 6.24]
4/12
7.96 [2.43, 26.06]
value for interaction = 0.294
value for interaction = 0.509
Drugs
GSTP1 Ile105Val
No
Ile/Ile
46/25
1 (reference)
31/40
1 (reference)
Ile/Val + Val/Val
43/12
0.46 [0.19, 1.05]
33/22
0.42 [0.19, 0.89]
Yes
Ile/Ile
39/36
1.67 [0.85, 3.34]
37/38
0.79 [0.40, 1.55]
Ile/Val + Val/Val
41/28
1.18 [0.60, 2.34]
40/29
0.50 [0.26, 0.98]
value for interaction = 0.439
value for interaction = 0.434
Drugs
GSTT1
No
T1
74/28
1 (reference)
54/48
1 (reference)
Null
15/9
1.65 [0.61, 4.26]
10/14
1.82 [0.72, 4.74]
Yes
T1
60/52
2.41 [1.33, 4.42]
56/56
1.23 [0.70, 2.18]
Null
20/12
1.59 [0.69, 3.67]
21/11
0.58 [0.25, 1.33]
value for interaction = 0.163
value for interaction = 0.042
Drugs
GSTM1
No
M1
48/19
1 (reference)
36/31
1 (reference)
Null
41/89
1.23 [0.55, 2.74]
28/31
1.49 [0.71, 3.16]
Yes
M1
42/25
1.61 [0.76, 3.45]
41/26
0.88 [0.43, 1.80]
Null
38/39
2.95 [1.47, 5.91]
36/41
1.51 [0.78, 2.91]
value for interaction = 0.457
value for interaction = 0.782
10 units/week; 5 cigarettes/day including during the past 5 years; presence of NSAIDs or antiplatelet therapy; ‡OR was adjusted by age, sex, H. pylori, smoking, alcohol, and NSAIDs or antiplatelet therapy.
